Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8291350 | 0.80 | AR (0.39) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL1067814 | 0.78 | TDP1 (0.44) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL1067661 | 0.78 | MAPT (0.38) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL8291348 | 0.77 | ALDH1A1 (0.41) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL8228999 | 0.71 | MAPK1 (0.37) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL19733666 | 0.66 | CYP3A4 (0.44) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL29465715 | 0.65 | KCNH2 (0.62) | TDP1TSHRMAPTMEN1POLB | |
| SCHEMBL1065088 | 0.65 | KCNH2 (0.62) | TDP1TSHRMAPTMEN1POLB | |
| SCHEMBL3973537 | 0.65 | MAPT (0.69) | TDP1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL8293148 | 0.64 | ERN1 (0.46) | MAPTLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | TDP1 926/4885TSHR 3869/4885MAPT 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.